Cel­lec­tis boosts its cof­fers in re­vised off-the-shelf CAR-T deal with Servi­er

Years be­fore the CAR-T ther­a­pies Kym­ri­ah and Yescar­ta hit the mar­ket, two French com­pa­nies joined forces in a quest to bring off-the-shelf im­munother­a­pies based on gene-edit­ed al­lo­gene­ic CAR-T cells to fruition.

Now, the play­ers Cel­lec­tis and part­ner Servi­er have amend­ed the terms of their col­lab­o­ra­tion, six years af­ter they first inked a deal to co-de­vel­op Cel­lec­tis’ lead prod­uct can­di­date, UCART19, in ad­di­tion to five oth­er prod­uct can­di­dates tar­get­ing sol­id tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.